1. The benzimidazoles albendazole and mebendazole exhibit selective toxicity for helminths over the mammalian host. Which property of their molecular target most precisely accounts for this selectivity?
A) They inhibit a mitochondrial enzyme present only in helminths and entirely absent from mammalian cells
B) They are activated to their toxic form exclusively by a helminth-specific reductase, remaining inert in the host
C) They bind with substantially higher affinity to parasite beta-tubulin than to mammalian beta-tubulin, exploiting structural differences in the colchicine-binding region
D) They are excluded from mammalian cells by host P-glycoprotein but freely enter helminth cells
E) They chelate calcium selectively within the helminth tegument, sparing host tissue
ANSWER: C
Rationale:
The selective toxicity of benzimidazoles rests on a differential binding affinity: the drugs bind parasite beta-tubulin substantially more avidly than mammalian beta-tubulin, owing to structural differences in the region overlapping the colchicine-binding site. Because host microtubules are far less affected at therapeutic concentrations, the worm's cytoskeleton and glucose uptake collapse while the host is largely spared.
Option A: Option A is incorrect; benzimidazoles act on tubulin, a cytoskeletal protein, not a helminth-exclusive mitochondrial enzyme.
Option B: Option B is incorrect; benzimidazoles are not prodrugs requiring helminth-specific reductive activation.
Option D: Option D is incorrect; selectivity arises from differential tubulin binding, not from host P-glycoprotein exclusion.
Option E: Option E is incorrect; calcium chelation in the tegument is not the benzimidazole mechanism and is unrelated to praziquantel's calcium-permeability effect.
2. Both albendazole and mebendazole are benzimidazoles, yet only one is the agent of choice for tissue-invasive cestode disease such as neurocysticercosis and echinococcosis. Which pharmacokinetic distinction best explains why albendazole, not mebendazole, fills that role?
A) Albendazole is absorbed appreciably (and more so with a fatty meal), achieving systemic and tissue concentrations adequate for tissue-dwelling larvae, whereas mebendazole is very poorly absorbed and remains largely confined to the gut lumen
B) Mebendazole is rapidly hydrolyzed by plasma esterases before it can reach tissue, whereas albendazole resists hydrolysis
C) Albendazole is actively transported across the blood-brain barrier by a saturable carrier that excludes mebendazole
E) Albendazole is administered parenterally for tissue disease, whereas mebendazole exists only as an oral formulation
ANSWER: A
Rationale:
The decisive distinction is oral absorption. Albendazole is absorbed to a clinically meaningful degree, and its absorption is further enhanced by a fatty meal because it is lipophilic, allowing it to reach the systemic and tissue concentrations required to act on tissue-dwelling larvae in neurocysticercosis and echinococcosis. Mebendazole is very poorly absorbed and stays largely within the gut lumen, which suits luminal intestinal nematodes but not tissue disease.
Option B: Option B is incorrect; the difference is in absorption, not plasma esterase hydrolysis of mebendazole.
Option C: Option C is incorrect; albendazole is not carried across the blood-brain barrier by a mebendazole-excluding active transporter, and its central penetration follows from systemic exposure.
Option D: Option D is incorrect; albendazole in fact undergoes substantial first-pass conversion to its active sulfoxide, and it does not bypass the liver.
Option E: Option E is incorrect; albendazole for tissue disease is given orally, not parenterally.
3. Ivermectin produces flaccid paralysis in susceptible parasites by acting on a specific ion channel. Which statement most precisely identifies that target and the basis for the drug's sparing of the mammalian host at therapeutic doses?
A) It activates voltage-gated sodium channels unique to nematode muscle, with no mammalian counterpart
B) It blocks the parasite nicotinic acetylcholine receptor, a receptor type humans entirely lack
C) It inhibits the parasite ryanodine receptor, depleting intracellular calcium stores selectively
D) It opens parasite voltage-gated potassium channels that are insensitive to the drug in mammals
E) It binds glutamate-gated chloride channels found in invertebrate nerve and muscle; humans lack these at peripheral neuromuscular sites, and the related central channels are largely shielded by the blood-brain barrier that normally restricts ivermectin entry
ANSWER: E
Rationale:
Ivermectin binds glutamate-gated chloride channels, increasing chloride influx and hyperpolarizing the cell to produce flaccid paralysis. These channels are an invertebrate feature; humans do not employ them at peripheral neuromuscular sites, and the related inhibitory channels in the human central nervous system are largely protected by the blood-brain barrier, which normally limits ivermectin entry into the brain. Both facts together account for selectivity.
Option A: Option A is incorrect; ivermectin does not activate voltage-gated sodium channels.
Option B: Option B is incorrect; humans do possess nicotinic acetylcholine receptors, and these are not ivermectin's target.
Option C: Option C is incorrect; the ryanodine receptor and calcium-store depletion are not the ivermectin mechanism.
Option D: Option D is incorrect; ivermectin does not act through voltage-gated potassium channels.
4. Praziquantel is described as having a dual, concentration-dependent action on susceptible flukes and tapeworms. Which description most precisely captures both components of this action?
A) At all concentrations it produces only flaccid paralysis by hyperpolarizing the tegument, with no immune component
B) At low concentrations it increases tegument calcium permeability, causing sustained contraction and spastic paralysis; at higher concentrations it vacuolizes and disrupts the tegument, exposing concealed surface antigens to host immune effector mechanisms
C) At low concentrations it inhibits tubulin polymerization; at higher concentrations it blocks folate synthesis
D) At low concentrations it blocks glutamate-gated chloride channels; at higher concentrations it agonizes nicotinic receptors
E) At all concentrations it acts solely by exposing antigens to the immune system, with no direct effect on worm musculature
ANSWER: B
Rationale:
Praziquantel acts on the worm tegument in a concentration-dependent manner. At low concentrations it raises tegument calcium permeability, producing sustained contraction and spastic paralysis; at higher concentrations it causes vacuolization and disruption of the tegument, exposing surface antigens normally hidden from the host so that immune effector mechanisms can attack the worm. The combination of paralysis and immune-mediated killing defines its dual action.
Option A: Option A is incorrect; praziquantel causes spastic, not flaccid, paralysis, and there is an immune component.
Option C: Option C is incorrect; tubulin inhibition and folate blockade are mechanisms of other drug classes.
Option D: Option D is incorrect; chloride-channel and nicotinic actions belong to ivermectin and pyrantel respectively.
Option E: Option E is incorrect because praziquantel does have a direct paralytic effect on the worm in addition to the immune component.
5. Praziquantel undergoes extensive first-pass metabolism by hepatic CYP3A4. A patient on rifampicin, a potent CYP3A4 inducer, requires treatment for schistosomiasis. Which statement most precisely describes the expected interaction and its management implication?
A) Rifampicin inhibits CYP3A4, markedly raising praziquantel levels and risking toxicity, so the dose must be reduced
B) Rifampicin and praziquantel do not interact because praziquantel is renally cleared unchanged
C) Rifampicin increases praziquantel bioavailability by enhancing intestinal absorption, improving efficacy
D) Rifampicin strongly induces CYP3A4, sharply lowering praziquantel plasma concentrations and threatening treatment failure, so co-administration should be avoided and an alternative arrangement made
E) Rifampicin converts praziquantel to a more active metabolite, so a lower praziquantel dose suffices
ANSWER: D
Rationale:
Rifampicin is a potent inducer of CYP3A4, the enzyme responsible for praziquantel's extensive first-pass metabolism. Induction sharply lowers praziquantel plasma concentrations, which threatens treatment failure; the appropriate response is to avoid co-administration and arrange an alternative (for example, deferring or substituting therapy) rather than relying on a subtherapeutic praziquantel exposure.
Option A: Option A is incorrect; rifampicin induces rather than inhibits CYP3A4, so levels fall, not rise.
Option B: Option B is incorrect; praziquantel is heavily metabolized by CYP3A4 rather than renally cleared unchanged, so the interaction is real.
Option C: Option C is incorrect; rifampicin does not improve praziquantel absorption or efficacy.
Option E: Option E is incorrect; rifampicin does not generate a more active praziquantel metabolite, and the net effect is loss of drug exposure.
6. Pyrantel and piperazine both paralyze intestinal nematodes, but by opposing electrophysiological mechanisms. Which pairing correctly distinguishes the two and states the consequence of combining them?
A) Pyrantel is a depolarizing nicotinic acetylcholine receptor agonist producing spastic paralysis, whereas piperazine produces hyperpolarizing (GABA-mediated) flaccid paralysis; because the effects oppose one another, the two drugs are antagonistic and should not be combined
B) Both are nicotinic agonists producing spastic paralysis, so they are synergistic and ideally combined
C) Pyrantel hyperpolarizes the worm while piperazine depolarizes it, but the two are synergistic
D) Both hyperpolarize the worm through chloride influx, making them interchangeable
E) Pyrantel blocks acetylcholine receptors to cause flaccid paralysis, whereas piperazine is a nicotinic agonist causing spastic paralysis
ANSWER: A
Rationale:
Pyrantel acts as a depolarizing agonist at the worm nicotinic acetylcholine receptor, producing persistent depolarization and spastic (rigid) paralysis. Piperazine produces an inhibitory, hyperpolarizing (GABA-mediated) effect and thus flaccid paralysis. Because depolarizing spastic paralysis and hyperpolarizing flaccid paralysis are physiologically opposing, the two drugs antagonize each other and should not be combined.
Option B: Option B is incorrect; piperazine is not a nicotinic agonist, and the drugs are not synergistic.
Option C: Option C inverts the mechanisms and wrongly calls them synergistic.
Option D: Option D is incorrect; pyrantel depolarizes rather than hyperpolarizes, so they are not interchangeable chloride-influx agents.
Option E: Option E reverses both drugs' actions: pyrantel is an agonist causing spastic paralysis, not a blocker, and piperazine causes flaccid, not spastic, paralysis.
7. Diethylcarbamazine (DEC) is predominantly microfilaricidal. Which statement most precisely characterizes its principal action against microfilariae?
A) It is strongly macrofilaricidal, rapidly killing adult worms while sparing microfilariae
B) It directly lyses microfilariae by forming pores in their cell membranes, independent of the host immune system
C) It reduces microfilarial motility and interferes with the arachidonic-acid-metabolite-mediated immune evasion of microfilariae, exposing their surface antigens to host immune attack; it is only weakly active against adult worms
D) It chelates iron required for microfilarial respiration, an effect unrelated to host immunity
E) It blocks glutamate-gated chloride channels in microfilariae, paralyzing them in the same manner as ivermectin
ANSWER: C
Rationale:
DEC is predominantly microfilaricidal. It reduces microfilarial motility and interferes with the arachidonic-acid-metabolite-mediated mechanisms by which microfilariae evade host immunity, thereby exposing their surface antigens to host immune effector attack. Its activity against adult worms is comparatively weak (it is not strongly macrofilaricidal).
Option A: Option A is incorrect; DEC is predominantly microfilaricidal, not strongly macrofilaricidal.
Option B: Option B is incorrect; the killing is substantially immune-mediated rather than a direct membrane-pore lysis independent of the host.
Option D: Option D is incorrect; iron chelation is not the DEC mechanism.
Option E: Option E is incorrect; the glutamate-gated chloride channel mechanism belongs to ivermectin, not DEC.
8. Praziquantel is the agent of choice across most trematode infections, but one important liver fluke does not respond to it. Which fluke is the exception, and what is the correct agent?
A) Schistosoma mansoni; the correct agent is triclabendazole
B) Clonorchis sinensis; the correct agent is albendazole
C) Paragonimus westermani; the correct agent is mebendazole
D) Opisthorchis viverrini; the correct agent is ivermectin
E) Fasciola hepatica; its tegument is inherently resistant to praziquantel, so triclabendazole is the agent of choice
ANSWER: E
Rationale:
Fasciola hepatica (liver fluke) is the notable trematode that does not respond to praziquantel because its tegument is inherently resistant; triclabendazole is the established agent of choice for fascioliasis.
Option A: Option A is incorrect; Schistosoma mansoni responds well to praziquantel and does not require triclabendazole.
Option B: Option B is incorrect; Clonorchis sinensis is treated with praziquantel, not albendazole.
Option C: Option C is incorrect; Paragonimus westermani (lung fluke) is treated with praziquantel, not mebendazole.
Option D: Option D is incorrect; Opisthorchis viverrini is treated with praziquantel, not ivermectin.
9. Among the intestinal and tissue-migrating nematodes, Strongyloides stercoralis is a recognized exception to the general benzimidazole-first rule for roundworms. Which statement is correct?
A) Mebendazole is the established first-line agent for strongyloidiasis, with ivermectin reserved for failures
B) Ivermectin is the first-line agent for strongyloidiasis because it is more effective against Strongyloides than the benzimidazoles, which have inferior efficacy against this parasite
C) Praziquantel is first-line for strongyloidiasis because Strongyloides is a tissue trematode
D) Diethylcarbamazine is first-line for strongyloidiasis as it is for all tissue-migrating nematodes
E) Pyrantel is first-line for strongyloidiasis because of its luminal spastic-paralysis action
ANSWER: B
Rationale:
Ivermectin is the first-line agent for strongyloidiasis. It is more effective against Strongyloides stercoralis than the benzimidazoles, whose efficacy against this parasite is inferior, which is precisely why Strongyloides is the exception to the benzimidazole-first rule for roundworms.
Option A: Option A is incorrect; benzimidazole efficacy against Strongyloides is inferior, so mebendazole is not the established first-line agent.
Option C: Option C is incorrect; Strongyloides is a nematode (roundworm), not a trematode, and praziquantel does not treat it.
Option D: Option D is incorrect; diethylcarbamazine is a filarial agent and is not first-line for Strongyloides or for all tissue-migrating nematodes.
Option E: Option E is incorrect; pyrantel is not the agent of choice for strongyloidiasis.
10. Benzimidazole resistance in helminths is most directly explained by a change in the drug's molecular target. Which molecular event is the principal mechanism, and which specific substitution is most strongly associated with high-level resistance?
A) Upregulation of P-glycoprotein efflux pumps; the F167Y substitution is the strongest marker
B) Increased glutathione conjugation of the drug; the E198A substitution is the strongest marker
C) Amplification of a folate-synthesis gene; no specific codon is implicated
D) A single-nucleotide polymorphism in the parasite beta-tubulin gene that alters the drug-binding site while preserving tubulin function; the codon 200 substitution (F200Y) is most strongly associated with high-level resistance
E) Loss of the glutamate-gated chloride channel; the F200Y substitution in that channel is the strongest marker
ANSWER: D
Rationale:
Because benzimidazoles act by binding beta-tubulin, the principal resistance mechanism is a single-nucleotide polymorphism in the parasite beta-tubulin gene that alters the drug-binding site while still permitting the tubulin to function; among the implicated codons (167, 198, 200), the codon 200 substitution (F200Y) is most strongly associated with high-level resistance.
Option A: Option A is incorrect; while efflux can contribute generally, the principal and most strongly associated benzimidazole-resistance change is a beta-tubulin SNP, and F167Y is not the strongest single marker.
Option B: Option B is incorrect; increased glutathione conjugation is not the principal mechanism, and E198A is not the strongest marker.
Option C: Option C is incorrect; benzimidazoles do not act on folate synthesis, so amplifying a folate gene would not confer resistance.
Option E: Option E is incorrect; the glutamate-gated chloride channel is the ivermectin target, not the benzimidazole target.
11. Ivermectin resistance, best characterized in veterinary nematodes, involves mechanisms distinct from benzimidazole resistance. Which combination of mechanisms is most characteristic of ivermectin resistance?
A) Mutations in glutamate-gated chloride channel subunit genes together with upregulation of P-glycoprotein drug-efflux pumps that reduce drug accumulation at the target
B) A beta-tubulin codon 200 substitution identical to that seen in benzimidazole resistance
C) Increased parasite folate synthesis bypassing the drug's antifolate action
D) Loss of the nicotinic acetylcholine receptor that ivermectin must agonize
E) Enhanced tegument calcium pumping that ejects the drug from the worm surface
ANSWER: A
Rationale:
Ivermectin resistance characteristically involves changes at and around its target: mutations in glutamate-gated chloride channel subunit genes that reduce drug binding, together with upregulation of P-glycoprotein efflux pumps that lower drug accumulation at the target.
Option B: Option B is incorrect; a beta-tubulin codon 200 substitution is the benzimidazole-resistance mechanism, not the ivermectin one.
Option C: Option C is incorrect; ivermectin is not an antifolate, so altered folate synthesis is irrelevant to its resistance.
Option D: Option D is incorrect; ivermectin acts on glutamate-gated chloride channels, not by agonizing a nicotinic acetylcholine receptor, so loss of that receptor would not confer ivermectin resistance.
Option E: Option E is incorrect; tegument calcium pumping relates to praziquantel's site of action, not ivermectin resistance.
12. In neurocysticercosis, a corticosteroid is given concurrently with antiparasitic therapy. Which pharmacokinetic interaction most precisely explains why albendazole, rather than praziquantel, is the preferred antiparasitic backbone in this combination?
A) Corticosteroids raise praziquantel cerebrospinal fluid levels, making it too toxic to use centrally
B) Corticosteroids inhibit albendazole absorption entirely, so praziquantel must be used despite the interaction
C) Corticosteroids reduce praziquantel cerebrospinal fluid concentrations, whereas albendazole's central nervous system penetration is not meaningfully reduced by concurrent corticosteroid, so albendazole maintains effective central exposure
D) Corticosteroids and praziquantel form an inactive chelate in the cerebrospinal fluid
E) Albendazole and corticosteroids are chemically identical in their central transport, so the choice is arbitrary
ANSWER: C
Rationale:
Concurrent corticosteroids reduce praziquantel cerebrospinal fluid concentrations, undermining its central efficacy in neurocysticercosis, whereas albendazole's central nervous system penetration is not meaningfully reduced by corticosteroids. Albendazole therefore maintains effective central exposure during the steroid co-treatment that neurocysticercosis requires, making it the preferred antiparasitic backbone.
Option A: Option A is incorrect; corticosteroids lower, not raise, praziquantel central levels.
Option B: Option B is incorrect; corticosteroids do not abolish albendazole absorption, and albendazole remains usable.
Option D: Option D is incorrect; there is no inactive corticosteroid-praziquantel chelate in the cerebrospinal fluid.
Option E: Option E is incorrect; albendazole and corticosteroids are not identical in central transport, and the choice is not arbitrary.
13. Before administering diethylcarbamazine or ivermectin in Central Africa, assessment of the patient's Loa loa microfilarial burden is mandatory. Which statement most precisely states the reason?
A) A high Loa loa burden inactivates both drugs, guaranteeing treatment failure without any safety concern
B) A high Loa loa burden prevents oral absorption of both drugs, so parenteral dosing is required
C) The assessment is needed only to confirm the diagnosis and has no bearing on safety
D) Loa loa is intrinsically resistant to both drugs, so the test is purely academic
E) In patients with a very high Loa loa microfilarial density, rapid drug-induced death of large numbers of microfilariae can precipitate a severe, potentially fatal encephalopathy, so the burden must be quantified before treating
ANSWER: E
Rationale:
When the Loa loa microfilarial density is very high, drugs that rapidly kill microfilariae (diethylcarbamazine and ivermectin) can trigger a severe and potentially fatal encephalopathy as enormous numbers of microfilariae die at once within central nervous system vessels. Quantifying the burden beforehand identifies high-risk patients and is therefore mandatory.
Option A: Option A is incorrect; the danger is from rapid microfilarial death, not drug inactivation or mere treatment failure.
Option B: Option B is incorrect; a high microfilarial burden does not block oral absorption.
Option C: Option C is incorrect; the assessment has direct and major safety implications, not merely diagnostic value.
Option D: Option D is incorrect; the concern is a life-threatening drug-induced reaction, not intrinsic resistance, so the test is far from academic.
14. Diethylcarbamazine is avoided for lymphatic filariasis mass drug administration in areas where onchocerciasis is co-endemic. Which statement most precisely explains this and states the substitute regimen?
A) Diethylcarbamazine is ineffective against lymphatic filariasis when onchocerciasis is present, so triclabendazole plus praziquantel is substituted
B) In onchocerciasis-co-endemic areas, diethylcarbamazine can provoke a severe Mazzotti-type reaction from the rapid death of Onchocerca volvulus microfilariae (including ocular harm), so ivermectin plus albendazole is used instead, while diethylcarbamazine plus albendazole is reserved for areas without onchocerciasis
C) Diethylcarbamazine is contraindicated only because it tastes unpleasant; ivermectin plus pyrantel replaces it
D) Onchocerciasis renders diethylcarbamazine unabsorbable, so intravenous niclosamide is substituted
E) Diethylcarbamazine works only against adult Onchocerca, so praziquantel plus mebendazole is substituted
ANSWER: B
Rationale:
In areas where onchocerciasis is co-endemic, diethylcarbamazine can provoke a severe Mazzotti-type reaction caused by the rapid death of Onchocerca volvulus microfilariae, including the risk of ocular injury; for this reason lymphatic filariasis mass drug administration uses ivermectin plus albendazole where onchocerciasis is present, reserving diethylcarbamazine plus albendazole for areas free of onchocerciasis.
Option A: Option A is incorrect; the issue is a dangerous reaction, not lack of antifilarial efficacy, and triclabendazole plus praziquantel is a fluke regimen.
Option C: Option C is incorrect; the contraindication is the Mazzotti reaction, not palatability, and pyrantel is not part of the regimen.
Option D: Option D is incorrect; onchocerciasis does not render diethylcarbamazine unabsorbable, and niclosamide is a tapeworm agent.
Option E: Option E is incorrect; the substitution rationale is the microfilaricidal reaction risk, not adult-only activity, and praziquantel plus mebendazole is not the filariasis regimen.
15. A second course of praziquantel given four to six weeks after the first improves cure rates in schistosomiasis. Which property of the drug most precisely accounts for the benefit of this delayed second dose?
A) Praziquantel induces its own metabolism, so a second dose is needed merely to overcome autoinduction
B) The first dose sterilizes adult worms but leaves their eggs, which the second dose then kills directly
C) Praziquantel accumulates slowly, so a second dose is required only to reach therapeutic plasma levels
D) Praziquantel is most active against adult worms and has limited activity against immature stages; schistosomula that were still maturing at the first dose survive it, and a second course weeks later catches them once they have matured into susceptible adults
E) The second dose is needed only because the first is routinely vomited and not absorbed
ANSWER: D
Rationale:
Praziquantel is most active against adult worms and has limited activity against immature stages. Schistosomula that were still maturing at the time of the first dose are relatively insusceptible and survive it; giving a second course four to six weeks later catches these worms once they have matured into susceptible adults, which is why the delayed second dose raises cure rates.
Option A: Option A is incorrect; the benefit is not about overcoming autoinduction.
Option B: Option B is incorrect; the second dose works by killing now-mature worms, not by directly killing eggs.
Option C: Option C is incorrect; the rationale is the maturation of immature worms, not slow drug accumulation.
Option E: Option E is incorrect; the second course addresses immature-stage survival, not routine vomiting of the first dose.
16. Pyrantel pamoate has a deliberately narrow systemic profile. Which statement most precisely characterizes its absorption, spectrum boundary, and a resulting clinical feature?
A) It is well absorbed systemically, active against Trichuris trichiura, and contraindicated in pregnancy because of high fetal exposure
B) It is well absorbed, active against all tissue-invasive helminths, and the agent of choice for strongyloidiasis
C) It is poorly absorbed and therefore largely confined to the gut lumen, is active against Ascaris, hookworm, and Enterobius but NOT against Trichuris trichiura, and its minimal systemic exposure underlies its acceptability in pregnancy
D) It is poorly absorbed, active against Trichuris but not Ascaris, and must be combined with piperazine for efficacy
E) It is completely unabsorbed, has no luminal activity, and works only against tissue cestodes
ANSWER: C
Rationale:
Pyrantel pamoate is poorly absorbed from the gut, which confines most of its action to the intestinal lumen. Its spectrum covers Ascaris lumbricoides, hookworm species, and Enterobius vermicularis, but it is not active against Trichuris trichiura, and its minimal systemic absorption is the basis for its acceptability in pregnancy.
Option A: Option A is incorrect on every count: pyrantel is poorly absorbed, is not reliably active against Trichuris, and is not contraindicated in pregnancy.
Option B: Option B is incorrect; it is not well absorbed, not active against tissue-invasive helminths, and not the agent of choice for strongyloidiasis.
Option D: Option D is incorrect; pyrantel is active against Ascaris but not Trichuris, and it must not be combined with piperazine because their mechanisms are antagonistic.
Option E: Option E is incorrect; pyrantel has luminal nematode activity and does not work against tissue cestodes.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.